Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

US Patent 9139654 · Granted Sep 22, 2015

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bispecific antibody molecules binding to CD3 and EGFRvIII2025
Methods of treating cancer by administering tumor necrosis factor (TNF) family l2025
Furnace shut off device2025
Bispecific antibodies specific for PD1 and TIM32025
Anti-FAP antibodies and methods of use2025
Combination therapy with targeted 4-1BB (CD137) agonists2025
Bispecific antigen binding molecules comprising anti-FAP clone 2122025
Stabilized immunoglobulin domains2025
Bispecific antibodies specific for OX402025
Antibodies binding to CD3 and CD192025
Antigen binding molecules comprising a trimeric TNF family ligand and encoding p2025
Bispecific antigen binding molecules capable of specific binding to CD40 and to 2024